SUO 2015 The Current Status of Adjuvant Systemic Therapy for RCC - Session Highlights

Washington, DC (UroToday.com) In today’s Adjuvant therapy for localized renal cancer session at the 2015 Society of Urologic Oncology, Dr Uzzo Robert from Fox Chase Cancer center presented the difficulties in finding effective adjuvant therapy for RCC. Dr Uzzo called adjuvant treatment for RCC “the elusive holy grail of surgery” as it will hopefully bridge the gap between incompletely effective surgical therapy and completely effective systemic therapy. 

SUO 2015 Impact of Renal Mass Biopsy on Renal Mass Management - Session Highlights

Washington, DC (UroToday.com): The role of renal mass biopsy in the management of small renal masses (SRM; defined as a cT1a mass) is increasing as the movement towards active surveillance of benign masses or indolent cancers increases. Stuart Wolf, Jr., MD, from University of Michigan presented data from his institution on a large cohort of patients with SRMs. He set out to answer four questions. The first question was whether renal mass biopsy (RMB) can

SUO 2015 Development of the Renal Cancer Follow-up Guidelines - Session Highlights

Washington, DC (UroToday.com) In today’s renal cancer session at the 2015 SUO, Dr. Sherri Donat discussed the process that goes into the development of renal cancer follow-up guidelines and critiques of those guidelines. The purpose of guidelines is to provide a framework for follow-up of localized renal neoplasms undergoing active surveillance or following definitive treatment. Moreover, guidelines provide guidance for ongoing evaluation of renal function, use of renal biopsy, timing/type of imaging, and survivorship considerations.

SUO 2015 Combination Checkpoint Inhibitors - Session Highlights

Washington, DC (UroToday.com): Dr. Hans Hammers presented today about the changing landscape in treatment of metastatic Renal Cell Carcinoma with immunotherapy.

SUO 2015 Designing the next generation of clinical trials - Session Highlights

Washington, DC (UroToday.com) There are currently no trials in support of adjuvant systemic therapy in renal cell carcinoma (RCC). In this session, Dr. Harshman discussed the current therapeutic landscape of advanced RCC and describes techniques for designing the next generation of clinical trials to minimize patient resources and shorten time to completion.

SUO 2015 PD-1 expression on Classical Monocytes (CM) is an independent predictor of cancer specific survival in clear cell Renal Cell Carcinoma - Poster Session

Washington, DC (UroToday.com):  Monocytes are an important component of innate and adaptive immunity due to their ability to phagocytose, produce cytokines, and present antigens.  They are characterized into three different subsets based on cell-surface markers—classical monocytes (CM), intermediate monocytes, and nonclassical monocytes.  Classical monocytes constitute up to 95% of all monocytes.  Monocytes migrate into tissue and are then called macrophages. 

SUO 2015 - Venous thromoboembolism following nephrectomy: thirty day incidence and risk factors from national multi-institutional data - Poster Session Highlights

Washington, DC USA (UroToday.com) In today’s SUO meeting poster session Matulewicz Richard and colleagues from Northeastern University presented their data on venous thromboembolism (VTE) after nephrectomies. It is known that VTE has significant consequences on surgical patients’ morbidity and mortality. The authors hypothesized that there are potentially modifiable risk factors that differentially influence the rate of VTE after open and minimally invasive (MIS) nephrectomy.

E-Newsletters

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.

Subscribe